نتایج جستجو برای: histon deacetylas inhibitors hdaci

تعداد نتایج: 188850  

2015
Hong Zong Dhavan Shah Katherine Selwa Ryan E Tsuchida Rahul Rattan Jay Mohan Adam B Stein James B Otis Sascha N Goonewardena

Histone deacetylase inhibitors (HDACi) are promising therapeutics for cancer. HDACi alter the epigenetic state of tumors and provide a unique approach to treat cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off-target effects have limited their use. To overcome some of the challenges of traditional HDACi, we sought to use a tumor-specific dendrimer...

Journal: :Molecular cancer therapeutics 2007
Maxy De los Santos Alberto Zambrano Ana Aranda

All-trans retinoic acid (RA) causes differentiation of neuroblastoma cells, and retinoids have been used in clinical trials in children with advanced neuroblastoma. Combination of RA with histone deacetylase inhibitors (HDACi) could result in improved antitumorigenic activity. We have examined the effect of the HDACi trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SA...

2010
Philippos Peidis Andreas I. Papadakis Kamindla Rajesh Antonis E. Koromilas

Histone deacetylase inhibitors (HDACi) comprise a family of chemotherapeutic agents used in the clinic to treat cutaneous T-cell lymphoma and tested for the therapy of other malignancies. Previous reports have shown that eIF2α phosphorylation is induced upon treatment with HDACi. However the kinase responsible for this phosphorylation or the biological significance of this finding is not yet es...

Journal: :Molecular cancer therapeutics 2011
Girija Dasmahapatra Dmitry Lembersky Minkyeong P Son Elisa Attkisson Paul Dent Richard I Fisher Jonathan W Friedberg Steven Grant

Interactions between the proteasome inhibitor carfilzomib and the histone deacetylase (HDAC) inhibitors vorinostat and SNDX-275 were examined in mantle cell lymphoma (MCL) cells in vitro and in vivo. Coadministration of very low, marginally toxic carfilzomib concentrations (e.g., 3-4 nmol/L) with minimally lethal vorinostat or SNDX-275 concentrations induced sharp increases in mitochondrial inj...

2016
Matthew Pace James Williams Ayako Kurioka Andrew B. Gerry Bent Jakobsen Paul Klenerman Nneka Nwokolo Julie Fox Sarah Fidler John Frater

In the search for a cure for HIV-1 infection, histone deacetylase inhibitors (HDACi) are being investigated as activators of latently infected CD4 T cells to promote their targeting by cytotoxic T-lymphocytes (CTL). However, HDACi may also inhibit CTL function, suggesting different immunotherapy approaches may need to be explored. Here, we study the impact of different HDACi on both Natural Kil...

2011
Sebastian Stintzing Ralf Kemmerling Tobias Kiesslich Beate Alinger Matthias Ocker Daniel Neureiter

Myelodysplastic syndrome (MDS) represents a heterogeneous group of diseases with clonal proliferation, bone marrow failure and increasing risk of transformation into an acute myeloid leukaemia. Structured guidelines are developed for selective therapy based on prognostic subgroups, age, and performance status. Although many driving forces of disease phenotype and biology are described, the comp...

Journal: :Molecular medicine reports 2014
Hou-Gen Lu Wang Zhan Lin Yan Rui-Ying Qin Yi-Peng Yan Zhen-Jiang Yang Gui-Chao Liu Gui-Qin Li Hai-Feng Wang Xing-Liang Li Zhi Li Lu Gao Guo-Qing Chen

Histone deacetylases (HDACs) are important in chromatin remodeling and epigenetic regulation of gene expression. Histone deacetylase inhibitors (HDACi) have highly effective anti-metastatic and anti-angiogenic activity in various types of cancer, while the molecular mechanisms involved in this process are not fully understood. In the present study, trichostatin A (TSA), a HDACi, was found to su...

2011
Michael Bordonaro Shruti Tewari Catherine E. Cicco Wafa Atamna Darina L. Lazarova

Butyrate, a fermentation product of fiber in the colon, acts as a histone deacetylase inhibitor (HDACi) and induces apoptosis in colon cancer (CC) cells in vitro. We have reported that the apoptotic effects of butyrate are dependent upon the hyperactivation of the Wnt/beta-catenin pathway. However, prolonged exposure of CC cells to increasing concentrations of butyrate results in the acquisitio...

2010
Leigh Ellis Roberto Pili

Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleio...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید